Ind-Swift Laboratories Surges to 52-Week High, Receives 'Hold' Rating from MarketsMOJO

Aug 02 2024 10:35 AM IST
share
Share Via
Ind-Swift Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on August 2nd, 2024. With a 'Hold' rating from MarketsMojo, the stock is currently trading higher than its moving averages and has outperformed the sector in today's trading session. In the past year, the stock has shown a remarkable 92.28% increase, indicating strong performance and potential for future growth.


Ind-Swift Laboratories, a microcap pharmaceutical company, has recently seen a surge in its stock price, reaching a 52-week high on August 2nd, 2024. The stock is currently trading at Rs 172.8, which is 3.07% away from its 52-week high. This positive performance has caught the attention of investors and analysts alike.

According to MarketsMOJO, a leading financial analysis platform, the stock has been given a 'Hold' rating. This indicates that while the stock is performing well, it may not be the best time to buy or sell. This neutral stance is based on the company's current financials and market trends.

In today's trading session, Ind-Swift Laboratories has outperformed the sector by 1.68%, with the stock touching an intraday high of Rs 170.15 (2.84%) and an intraday low of Rs 160.8 (-2.81%). This shows a strong performance and volatility in the stock.

Furthermore, the stock is currently trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This indicates a positive trend and potential for further growth.

In the past year, Ind-Swift Laboratories has shown a remarkable performance, with a 92.28% increase in its stock price. In comparison, the Sensex has only seen a 23.24% increase. This shows the company's strong performance and potential for future growth.

Overall, Ind-Swift Laboratories is a promising microcap company in the pharmaceutical industry, with a strong stock performance and positive market sentiment. Investors and analysts will continue to monitor the company's progress and financials to make informed decisions.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News